(Sharecast News) - Drugmaker AstraZeneca said on Monday that its systemic lupus erythematosus treatment Saphnelo (anifrolumab) hsd received US Food and Drug Administration approval for self‑administration via a once‑weekly autoinjector, the Saphnelo Pen.
AstraZeneca said the FDA approval, for adults also receiving standard therapy, follows its recent Phase III TULIP‑SC trial,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE